- Home
- CRNC vs CLLS Comparison
CRNC vs CLLS Comparison
Compare CRNC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNC | CLLS |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | France |
| Employees | 1300 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.6M | 394.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRNC | CLLS |
|---|---|---|
| Price | $8.14 | $1.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $10.25 | $8.33 |
| AVG Volume (30 Days) | ★ 541.2K | 158.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,781,000.00 | N/A |
| Revenue This Year | $27.18 | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $1.25 |
| 52 Week High | $13.74 | $5.48 |
Technical Indicators
Market Signals| Indicator | CRNC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.